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Studies of normal human factor VIII/vW factor protein indicate that there is a requirement of a full complement of penultimate galactose for the maintenance of a normal multimeric structure. Release of penultimate galactose by (-galactosidase or modification by galactose oxidase results in loss of the largest molecular weight multimers and increased numbers of intermediate and smaller multimers. In contrast, terminal galactose on the factor VIII/vW factor protein does not appear to play a significant role in the maintenance of the multimer organization. The abnormalities in multimeric structure and molecular size were demonstrated by NaDodSO4/polyacrylamide/agarose gel electrophoresis, NaDodSO4/glyoxyl-agarose electrophoresis, and sucrose density ultracentrifugation. These studies indicate that the penultimate galactose plays a role in the maintenance of the largest multimers of the factor VIII/vW factor protein. This may explain why, in some patients with variant forms of vW disease, a carbohydrate abnormality also may affect the multimeric structure of the plasma factor VIII/vW factor protein.
The factor VIII/von Willebrand (VW) factor protein circulates as a series of oligomers with molecular weights estimated to be from -1.0 x 10' to 20 X 106. The subunit(s) of these oligomers has a molecular weight of ""230,000 (1, 2) . The mechanism of the formation of the multimers is thought to be primarily dependent on dilsulfide bond linkages (3) . Subunits combine to form dimers, and these dimers combine by subsequent disulfide bonds, resulting in a series of oligomers of various molecular weights. Within the oligomer populations there are significant functional differences because the vast majority of the vW factor activity both in vivo and in vitro appears to be associated with the largest multimers (4, 5) . This has been demonstrated both in studies of biochemical alterations in the multimeric structure of the normal factor VIII/vW factor protein and in descriptions of the abnormalities of the factor VIII/vW factor proteins in patients with vW disease (4, 5) . Further, it has been demonstrated that the binding of the vW factor protein to platelets and subsequent agglutination of platelets is related preferentially to the presence of the largest multimers compared to the intermediate or smaller multimers (4, 5) . Previous reports have elucidated the importance of penultimate galactose in the expression of vW factor activity (6, 7) , but these studies did not examine the multimeric structure.
We report here that the largest multimers of the normal factor VIII/vW factor protein are dependent on a full complement of carbohydrate because removal of the penultimate galactose of the factor VIII/vW factor protein or its modification by galactose oxidase results in the disappearance of the largest multimers, with a concomitant increase in intermediate and smaller multimers and a decrease in vW factor activity. These studies suggest that some of the defects of the multimeric structure described in variant forms of vW disease may be related to a decreased carbohydrate content of the protein.
MATERIALS AND METHODS
The factor VIII/vW factor protein was purified from cryoprecipitate obtained from normal blood donors by column chromatography on Sepharose 4B as described (5) . The material was judged to be >95% free of other proteins by NaDodSO4/polyacrylamide gel electrophoresis with and without the presence of reducing agents. The specific activities associated with the factor VIII/vW factor protein were: vW factor, 126 units/mg; factor VIII-related antigen (Ag), 143 units/mg; and factor VIIIcoagulant activity, 48 units/mg. Protein concentration was estimated by the method of Lowry (8) .
Pooled normal plasma was obtained from 30 normal donors who were not taking medication. The plasma was pooled and stored at -700C. Plasma from two patients with severe vW disease (factor VIII coagulant activity, <5%; vW factor, <5%; and factor VIII-related Ag, <5%; bleeding time, >30 min) was obtained and stored identically to normal plasma.
Assays for factor VIII coagulant activity, factor VIII-related Ag, and vW factor and crossed antigen-antibody electrophoresis were performed as described (9) .
Electrophoresis. NaDodSO4/glyoxyl-agarose electrophoresis was performed by the method of Hoyer and Shainoff (10).
The antibody used was either "2I-labeled goat or rabbit antihuman factor VIII/vW factor protein antibody (9) . Acrylamide/ agarose electrophoresis was performed by using 2% acrylamide/0.5% agarose and was modified as described by Perret et al (11) . Electrophoresis was carried out at 8 mA per gel. The gel length was 120 mm, and the bromophenol blue marker dye usually reached the bottom within 5 hr ± 20 min.
Ultracentrifugation was performed in a Beckman L265B ultracentrifuge. A 40-ml linear 10-40% (wt/vol) sucrose gradient was prepared in imidazole/saline buffer (0.02 M imidazole/0. 14 M NaCl, pH 7.2) and was centrifuged at 100,000 x g at 4°C for 17 hr. Fifty micrograms of factor VIII/vW factor labeled with 3H or 50 ,Ag of carbohydrate-modified factor VIII/vW factor labeled with 3H was placed in 2 ml of imidazole/saline buffer or plasma from patients with severe vW disease. The intact and carbohydrate-modified factor VIII/vW factor proteins were subjected to ultracentrifugation simultaneously. The was prepared from Clostridium perfringens (Worthington), purified by affinity chromatography as described (6) , and stored in acetate buffer (pH 5.5) containing 3% bovine albumin, and
(ii) ,( galactosidase, which was prepared from the Streptococcus pneumoniae cultures as described (6) (gift of G. Ashwell). The galactose oxidase was purified as described (6) . All enzymes were tested for protease activity by incubation with ['4C]globin, by incubation with the intact factor VIII/vW factor protein, and by measuring factor VIII coagulant activity (6) .
The factor VIII/vW factor protein was incubated with the various enzymes as follows: (i) neuraminidase was at 0.02-0.03 units per mg of factor VIII/vW factor protein (1 unit of enzyme is defined as the amount that releases 1 j.mol of sialic acid per min at 370C from a, glycoprotein); (ii) (B-galactosidase was at 0.002-0.004 units per mg of factor VIII/vW factor protein; and (iii) galactose oxidase was at 40 ,ug per mg of factor VIII/vW factor protein, and the horseradish peroxidase in this mixture was at 10 ,ug of enzyme per mg of factor VIII/vW factor protein. All incubations were performed at 37°C for various periods of time. Intact factor VIII/vW factor protein to which buffer was added and incubated for identical time periods served as a control for all experiments described.
Carbohydrate Assay Procedures. The total sialic acid was measured after hydrolysis of the factor VIII/vW factor protein in 0.05 M H2SO4 at 800C for 60 min by utilizing N-acetylneuraminic acid as the standard (12) . Free sialic acid was measured after treatment with the Clostridium perfringens neuraminidase. Penultimate galactose was measured by the enzymatic action of -galactosidase on the asialo factor VIII/vW factor protein, forming asialo-agalacto protein, and the free galactose was measured in an assay with galactose dehydrogenase (13) . Total galactose was determined by hydrolysis in 2 M hydrochloric acid at 1000C for 90 min. After hydrolysis of the intact factor VIII/vW factor protein, the sample was evaporated to dryness, reconstituted in half the original volume in water, reevaporated, and resuspended. The sample was then assayed for free galactose as described above. RESULTS The sialic acid content of the factor VIII/vW factor protein was 145 ± 12 nmol/mg or 33 mol per 230,000-dalton subunit (n = 6). Treatment with neuraminidase for 2 hr released >93% of the sialic acid (n = 6). Total galactose measured by acid hydrolysis was 205 ± 18 nmol/mg of factor VIII/vW factor protein or 47 mol per subunit (n = 6). Treatment of the intact factor VIII/vW factor protein with f3-galactosidase resulted in the release of 39 ± 6 nmol/mg of factor VIII/vW factor protein or 9 mol per subunit. Treatment of the asialo factor VIII/vW factor protein with (3galactosidase released 171 ± 20 nmol/mg of factor VIII/vW factor protein or a total of 39 mol per subunit. Of the 171 nmol of galactose released, 132 nmol/mg or 30 mol per subunit were penultimate and 39 nmol/mg or 9 mol per subunit were terminal. Thus, 34 nmol/mg or 8 mol per subunit of the total galactose could not be released by (-galactosidase.
Treatment of the intact factor VIII/vW factor protein with neuraminidase, ,B-galactosidase, or galactose oxidase did not result in the loss of procoagulant or vW factor activity. However, treatment of the asialo factor VIII/vW factor protein with /& galactosidase resulted in a time-dependent decrease of vW fac- , and asialo-agalacto (n) factor VIII/vW factor proteins were tested for vW factor activity over 24 hr. The vW factor activity of the asialo and the intact factor VIII/vW factor proteins did not significantly change. Thirty-nine nanomoles per mg of galactose were released from the intact factor VIII/vW factor protein, and the penultimate galactose (A) released from the asialo factor VIII/vW factor protein treated with 3-galactosidase at 1 hr was 33 nmol/mg, at 2 hr was 47 nmol/mg, at 4 hr was 63 nmol/mg, at6 hrwas 73 nmol/mg, and at 24 hr was 132 nmol/ mg. tor activity that correlated well with the release of the penultimate galactose (Fig. 1) . Treatment of the asialo factor VIII/ vW factor protein with galactose oxidase also resulted in a timedependent decrease in vW factor activity (data not shown). All of the enzymes used in this report were free of protease activity.
Examination of the results of the multimeric structure of the factor VIII/vW factor protein in these studies revealed marked differences between the material before and after removal or modification of the penultimate galactose. Agarose/acrylamide electrophoresis of the purified protein clearly demonstrated the loss of the slowest migrating bands and the largest multimers in the asialo-agalacto material. These studies were confirmed by using glyoxyl-agarose electrophoresis in which asialoagalacto factor VIII/vW factor definitely showed the loss of the largest multimers (Fig. 2) . Not only did the largest multimeric forms of the asialo-agalacto protein disappear, but an increase Proc. Natl. Acad. Sci. USA 80 (1983) Proc. NatL Acad. Sci. USA 80 (1983) 
Glyoxyl-agarose electrophoresis radioautograph. Lanes: A, pooled normal plasma; B, plasma from a patient with severe vW disease; C, factor VIII/vW factor protein with no enzyme treatment; D, the same material as in lane C but treated for 6 hr with (-galactosidase; E, factor VIII/vW factor protein after 6 hr of incubation with neuraminidase (asialo protein); F, the asialo factor VUI/vW factor protein treated with (-galactosidase for 6 hr (asialo-agalacto protein); G, the asialo factor VIIh/vW factor protein treated with galactose oxidase for 6 hr (modified galactose). In both lanes F and G, the loss of the largest multimeric structures is apparent with an increase in the amount of intermediate and smaller multimers. Lanes C-G contain identical amounts of protein (final concentration, 13 ng).
of antibody-radiolabeling of the intermediate and smaller multimers was apparent in the asialo-agalacto factor VIII/vW factor protein (Fig. 3) . In comparison, the intact factor VIII/vW factor protein treated only with 3-galactosidase (and not neuraminidase) did not change. Similar results were seen when galactose oxidase was incubated with asialo factor VIII/vW factor protein (Fig. 3) . In contrast, the galactose oxidase did not change the multimer composition of intact factor VIII/vW factor protein (data not shown).
The above-mentioned change(s) in multimeric structure were determined in the presence of NaDodSO4. In an effort to determine whether one would see the same alterations of multimeric structure of the asialo-agalacto factor VIII/vW factor without the use of NaDodSO4, ultracentrifugation was performed of the asialo, the asialo-agalacto, and the intact factor VIII/vW factor protein, and the intact factor VIII/vW factor protein treated with 3-galactosidase. As shown in Fig. 4 , there was a marked shift of the asialo-agalacto factor VIII/vW factor 5,000
A-A 4,000 - , and asialo-agalacto (A-A) factor VI/vW factor proteins were analyzed on separate gradients centrifuged at the same time. The 40% sucrose starts in tube 1, and 10% sucrose is in tube 40. The intact and asialo factor VII/vW factor proteins have the same positions in the gradient profile, whereas the asialo-agalacto factor VIII/vW factor protein is shifted, indicating a reduced molecular weight. The recovery of the radioactivity or factor VIII-related Ag ranged between 44 51% for all samples subjected to ultracentrifugation.
protein during ultracentrifugation, indicating that there had been a loss of the largest molecular weight structures and an increase in the intermediate and smaller molecular weight structures (Fig. 4) . Analysis of the intact factor VIII/vW factor and asialo protein revealed almost identical patterns when monitored by radioactivity per tube or by factor VIII-related Ag per tube.
DISCUSSION
The carbohydrate moiety(ies) of the human factor VIII/vW factor protein has been shown to be important in the expression of vW factor activity (6, 7) and the intravascular survival (14) . Removal of >90% of the sialic acid of the factor VIII/vW factor protein has been reported by some to result in a loss of -50% vW factor activity (14) , while other studies have indicated no change in vW factor activity after desialylation (6, 15 (6, 7) .
The only studies involving the role of carbohydrate in factor VIII/vW factor survival involve the infusion of human material into dogs (14) . In these studies, infusion of human asialo factor VIII/vW factor in dogs showed a shorter intravascular survival than that.of the intact protein. The studies presented here add another dimension to the role of carbohydrate in factor VIII/ vW factor structure or function, or both.
We have shown that the integrity of the largest multimers of the factor VIII/vW factor protein are dependent on penultimate galactose. Removal of the penultimate galactose of the factor VIII/vW factor protein results in a dramatic change in the multimeric structure. The asialo-agalacto factor VIII/vW factor shows a loss of the larger molecular weight oligomers, an increase in the smaller molecular weight oligomers, and a decrease of vWfactor activity. These changes of multimeric structure are related to the amount of galactose released (Fig. 3) . In contrast, the procoagulant activity did-not change after any of the enzyme modifications of the factor VIII/vW factor protein.
We have demonstrated these changes in molecular size of the multimers by agarose/acrylamide gel electrophoresis and glyoxyl-agarose electrophoresis with NaDodSO4 and by ultracentrifugation without the presence of any denaturating agent. When the intact factor VIII/vW factor protein was treated with the neuraminidase, in 8 of 11 studies the asialo factor VIII/vW factor protein showed no change in its vW factor activity or multimeric structure as assessed by glyoxyl-agarose gel electrophoresis or position after ultracentrifugation. Likewise, the subunit-structure of the reduced protein in NaDodSO4/polyacrylamide gel electrophoresis showed no change(s).
We considered the possibility that these findings were related to proteolysis of the factor VIII/vW factor protein by proteases contaminating the enzyme preparations. However, we could not detect protease activity utilizing the ['4C]globin chain assay. Incubation of the ,3galactosidase or galactose oxidase with the intact protein did not change the multimeric structure or the vW factor activity. These changes only occurred when these enzymes were added to the asialo factor VIII/vW factor. Other strong evidence again-st proteolysis is our finding that the factor VIII coagulant activity did not change after glycosidase treatment because this activity is quite susceptible to activation or destruction by proteases. Lastly, we found that the disappearance of the largest multimers from the agalacto factor VIII/vW factor protein was accompanied by an apparent increase in inMedical Sciences: Gralnick et aL 2774 Medical Sciences: Gralnick et aLP termediate and smaller multimers, and no bands of altered migration were seen (Figs. 2 and 3) .
These changes in multimeric structure of the asialo-agalacto factor VIII/vW factor protein may be related to a form of ligand interaction between penultimate galactose residues within the factor VIII/vW factor protein, resulting in the formation of larger multimers; or there may be another protein not yet identified that is a structural protein to which the multimers are bound, in part, by penultimate galactose bonds. In either instance, alteration of the penultimate galactose would result in a decrease in the size of the multimers. These observations are important not only in understanding the formation of the largest oligomers in the factor VIII/vW factor protein but also in explaining some of the molecular defects that previously have been described in variants of vW disease.
We recently have described patients with vW disease whose factor VIII/vW factor protein is deficient in carbohydrate and lacks the largest multimers (16) . Comparison of the multimeric structure of the vW disease factor VIII/vW factor protein with that of the normal factor VIII/vW factor protein after removal of sialic acid and penultimate galactose reveals a marked similarity. Thus, in some forms of vW disease, a deficiency of the penultimate galactose could result in the inability of the factor VIII/vW factor protein to form the largest multimers. This would be one mechanism for explaining the association of carbohydrate deficiency and an altered multimeric structure of the factor VIII/vW factor protein.
